(All fields required)
Please enter a valid email.
Please enter your name.
The Grimes lab investigates the interface between normal and malignant blood development. The lab uses state of the art biological and molecular tools to delineate transcriptional and microRNA signaling.
As a biomedical engineering major at the University of Cincinnati, I am currently working as a student co-op and am performing my research capstone on the effectiveness of different RNA therapeutics to combat acute myelogenous leukemia and severe congenital neutropenia. This research will hopefully lead to a better understanding of the pathology behind the accumulation of myeloid progenitors and novel therapies to treat forms of leukemia and severe congenital neutropenia.
Research Associate. I received a PhD in Chemistry from Hokkaido University in Japan, and have been studying the cell signaling in the field of cancer and obese-related diabetes. I am studying the molecular signaling mechanisms underlying the regulation of stemness in Acute Myeloid Leukemia (AML) cells, particularly those underlying novel therapies for AML leukemia initiating cells (LIC). AML LIC are important in context of minimal residual disease. When modern chemotherapeutic regimens fail to eradicate LIC, they are able to re-initiate the leukemia, leading to relapse. Thus, LIC are not only important for the progression of AML, but also the recurrence of AML after conventional treatments.
Currently a postdoctoral fellow in the Grimes' laboratory, Sara is interrogating the role of specific microRNAs in AML by
A NIH NIEHS T32 training grant and a $40,000 CancerFree Kids Award (PI: Meyer) currently supports Sara’s research. She was previously supported by a 2-year $100,000 Cancer Research Fellowship awarded by the Ladies Auxiliary to the Veterans of Foreign Wars and an NIH NHLBI T32 training grant. Sara completed her PhD in Cancer and Cell Biology at the University of Cincinnati (2009) and BS in Molecular and Cellular Biology at the Ohio University (2004).
I am a second year PhD student in the Molecular and Developmental Biology Program here at Cincinnati Children’s. Since I am interested in gene regulation and leukemia, Dr. Grimes’ research is a great fit for me. I am currently working on characterizing a family of STAT5 inhibitor compounds and the underlying mechanisms of their cytotoxic effects on AML cells. Prior to joining the MDB program, I graduated from the University of Louisville in 2011 with an MEng in Biomedical Engineering and spent a year as a Research Assistant at Cincinnati Children’s.
As a post doc I am focusing on Gfi1 dependent transcriptional regulation and epigenetic mechanisms in normal hematopoiesis and neutropenia.
Technician and Lab ManagerI study the both normal T cell development and transformation and am interested in the necessary cofactors for Gfi1 mediated repression in T lymphocytes.
Click image for caption.
From Left to Right: Dr. Kohei Masuda, Michael Woodmansee, David Muench, Dr. Adre Olsson, David Lee, Dr. Lee Grimes, Dr. Sara Meyer.
H. Leighton Grimes, PhD
Phone: 513-636-6089Fax: 513-636-5355Lee.Grimes@cchmc.org
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2013 Cincinnati Children's Hospital Medical Center